Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica LSE:OXB London Ordinary Share GB0006648157 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.05p +0.58% 8.60p 8.56p 8.60p 8.60p 8.56p 8.56p 317,595 12:54:41
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27.8 -20.3 -0.6 - 267.21

Oxford Biomedica Share Discussion Threads

Showing 100851 to 100874 of 100875 messages
Chat Pages: 4035  4034  4033  4032  4031  4030  4029  4028  4027  4026  4025  4024  Older
DateSubjectAuthorDiscuss
24/11/2017
11:44
FH, let`s hope for news of another deal as alluded to by JD before the end of 2017. Then DLBCL approval, earnings and progress by partners e.g. Orchard will hopefully increase the market cap.
marcusl2
24/11/2017
10:17
All welcome here. I assume the slogan was a jest in poor taste.
plutonian
24/11/2017
10:03
Don't plan to to surrender any shares for a some years. Thenk ye!
fhasson
24/11/2017
09:52
That is only my guess. No Surrender.
marcusl2
24/11/2017
09:37
MarcusExcellent feedback So ballpark approval may be with us by New Year. The upcoming ASH conference presentations fore mentioned in your earlier posts is bound to galvanise the direction of the decision makers. Go raibh maith agat
fhasson
24/11/2017
09:18
FH, it`s the same drug CTL019 that has been through scrutiny already. Safety is excellent and efficacy super for these highly pre-treated dying patients. Efficacy should improve if given earlier in the disease. The FDA is getting quicker at approving and expanding indications. I think approx two months but others on here will have a better idea than me. EMA not so sure. Here is an example; AstraZeneca Plc’s Lynparza was approved on Aug. 17 for use in ovarian cancer patients regardless of whether the patients carried a genetic mutation called BRCA. That surprised analysts, who had expected the label to only include BRCA positive patients, which were the subject of AstraZeneca’s main clinical trial. The broader label meant that Lynparza was comparable to Tesaro Inc.’s competing treatment, which had shown in trials that it worked for both BRCA positive and negative patients. HTTPS://www.bloomberg.com/news/articles/2017-10-06/flurry-of-drug-approvals-has-wall-street-eyeing-pharma-profits
marcusl2
23/11/2017
23:18
Marcus Interesting and very promising results with DLBCL studies presenting at ASH in December Do we have any idea on likely approval dates from FDA and their European counterparts for DLBCL and our Kymriah? Some tangible date could spur us on !Many thanks
fhasson
23/11/2017
14:35
I think the main one for us is DLBCL so roll on approval.39.5% CR No deaths were attributed to CTL019. No CRS or neurologic event associated deaths occurred. CONCLUSIONS: CTL019 produces high response rates with 95% of CRs at 3 months being sustained at 6 months in a cohort of highly pretreated adult patients with r/r DLBCL, results which confirm the findings of our earlier interim analysis. Centralized manufacturing was feasible in the first global study of CAR T cell therapy in DLBCL. CRS and other AEs could be effectively and reproducibly managed by appropriately trained investigators without treatment-related mortality. HTTPS://ash.confex.com/ash/2017/webprogram/Paper105399.html
marcusl2
23/11/2017
14:25
Based on these results and other recently published work (Tasian, Kenderian et al, Blood 2017) we propose to proceed with a clinical trial of lentivirally transduced CART123, followed by CART cell depletion with alemtuzumab, and a rescue allogeneic stem cell transplant. HTTPS://ash.confex.com/ash/2017/webprogram/Paper104118.html
marcusl2
23/11/2017
14:12
Introduction: Chimeric antigen receptor modified T cells directed against CD19 (CART19) has demonstrated efficacy in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) with durable complete remissions (CR) [Schuster et al. Blood 2016 (abstract 3026); Kochenderfer et al. Blood 2010; Turtle et al. Sci Transl Med 2016 ]. However, non-responding patients require novel therapeutic approaches. Pembrolizumab, an anti-PD1 checkpoint inhibitor, is an attractive next therapeutic option given its T cell-mediated mechanism of action. Anecdotally, we observed responses in patients treated with PD1 blockade after CART19 (Chong et al. Blood 2017). Based on these observations, we are conducting a clinical trial of pembrolizumab in patients with B cell non-Hodgkin lymphomas expressing CD19 who are r/r after CART19. HTTPS://ash.confex.com/ash/2017/webprogram/Paper103452.html
marcusl2
23/11/2017
14:10
Conclusion In the first study of humanized anti-CD19 CAR T cells, CTL119 induced CR in 100% of patients with no prior CAR T cell exposure, with a 12-mo RFS of 82%. In the retreatment setting, 56% of patients with poor or transient response to prior murine CD19-directed CAR T cells achieved CR. CTL119 can induce durable remissions without further therapy in children and young adults with relapsed/refractory B-ALL. HTTPS://ash.confex.com/ash/2017/webprogram/Paper103343.html
marcusl2
23/11/2017
13:45
HTTPS://www.ge.com/reports/survivor-womans-battle-leukemia-pointing-way-future-healthcare/ Just a fortnight until ASH if nothing else happens HTTPS://ash.confex.com/ash/2017/webprogram/start.html#srch=words%7Ccarl%20june%7Cmethod%7Cand%7Cpge%7C1%7CbyDayany%7Cany%7CbySymposiumany%7Cany%7CbyAudienceany%7Cany HTTPS://ash.confex.com/ash/2017/webprogram/Paper105399.html
marcusl2
23/11/2017
10:53
Just speculating re spin-outs, financing; HTTPS://knect365.com/partnering-insight/article/4a0c1503-30e0-4513-a56f-9ec677cee97d/12-vcs-who-matter-in-biotech-but-you-never-read-about Ben Auspitz, F-Prime Capital. “Best gene/cell therapy VC I can think of,” wrote one VC. OK, let’s check that. Auspitz is a co-founder of Dimension Therapeutics, a public gene therapy company. He’s also co-founder of Orchard Therapeutics, which debuted last year with a $33 million Series A and a couple former GSK employees who played key roles on Strimvelis, the EU-approved gene therapy for severe combined immunodeficiency disorder a.k.a “bubble boy” disease. That drug has gotten off to a well-documented slow start, but it’s still a milestone in gene therapy. Beyond those deals, Auspitz has invested in Ultragenyx Pharmaceutical (market cap, $2.06 billion), REGENX Biosciences (market cap, $833 million), Symbiomix Therapeutics (recently won FDA approval for antibiotic for gynecologic infections), Precision Biosciences, and Unum Therapeutics. He’s currently on the board of Compass Therapeutics, a cancer combo immunotherapy company that raised $120 million last year.
marcusl2
23/11/2017
10:29
Feels more like weedkiller to me
sddavies1
23/11/2017
10:09
Looks like some are simultaneously applying manure to the price though.
small crow
23/11/2017
10:05
Yes Harry, OXB being part of this is wonderful. Further good news on Novartis` CAR Ts, more deals and some miracle grow applied to the share price would be welcomed.
marcusl2
23/11/2017
09:52
Tremendous Marcus. Good news that also puts everything else into perspective.
harry s truman
23/11/2017
09:47
HTTPS://www.youtube.com/watch?v=uINcsXf7MCs
marcusl2
23/11/2017
09:31
HTTP://www.oncologytube.com/video/the-evolution-of-car-t-cell-therapy/10002454 HTTPS://youtu.be/7LKnNAh-_98?t=7
marcusl2
22/11/2017
19:16
Not the sort of unlicensed use we were talking about the other day. BTW Plutonian thanks for that good link which made it all clear (and gratifyingly seems I'd been talking sense haha!). Edit: or at least not complete rubbish. rrr
rrr
22/11/2017
18:24
HTTP://www.bbc.co.uk/news/world-us-canada-41990981
marcusl2
22/11/2017
17:34
Thanks, interesting. They have been strengthening their team for pre-clinical research in ophthalmology, CNS & cancer.
marcusl2
22/11/2017
15:57
NAK looks like a dog about to have its day!!
phil1969
22/11/2017
15:46
Muscular dystrophy, from memory, would need big load but on a bus ATM .. will check later.
small crow
Chat Pages: 4035  4034  4033  4032  4031  4030  4029  4028  4027  4026  4025  4024  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20171124 13:11:29